Ensayo PrECOG 0905: Gefitinib frente a midotuximab más quimioterapia intensiva para la leucemia mieloide aguda con mutación FLT3 de diagnóstico reciente – aml-hub.com
Ensayo PrECOG 0905: Gefitinib frente a midotuximab más quimioterapia intensiva para pacientes con leucemia mieloide aguda con mutación FLT3 de diagnóstico reciente (aml-hub.com)
Contenido completo del articulo
We summarize the key findings from the phase II PrECOG 0905 trial evaluating the efficacy of gilteritinib vs midostaurin in combination with intensive chemotherapy in patients with newly diagnosed FLT3-mutated AML.
Productos relacionados con este articulo
Estos productos se asociaron automaticamente a partir del titulo, el resumen y el contenido del articulo.
Preguntas frecuentes
Which products are related to this article?
The system matched these relevant products from the article content: Lucius Gefitinib – Comprar en línea Lucius Gilteritinib – Comprar en línea GILLIDX Gilteritinib 40 mg.
How can I view the medicines discussed in this article?
Use the related product cards below the article to review available specifications, prices, product information, and reviews.
Does this article replace advice from a doctor or pharmacist?
No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.